Provention Bio, Inc. (PRVB)

$ 4.41
+0.04 (+0.92%)
Symbol PRVB
Price $ 4.41
Beta 2.724
Volume Avg. 0.62M
Market Cap 0.279B
Shares () -
52 Week Range 4.33-15.98
1y Target Est -
DCF Unlevered PRVB DCF ->
DCF Levered PRVB LDCF ->
ROE -82.57% Strong Sell
ROA -76.76% Strong Sell
Operating Margin -
Debt / Equity 17.72% Neutral
P/E -
P/B 2.08 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest PRVB news

Mr. Ashleigh Palmer
Nasdaq Global Select

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. The company was incorporated in 2016 and is headquartered in Red Bank, New Jersey.